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Abstract
This article reviews the clinical practice guidelines for head and neck oncology focusing on the management of head and neck cancers of unknown primary (CUP). The
primary purpose of this series is to raise awareness of the current guidelines in head
and neck oncology by reviewing the recommendations and the evidence supporting
such recommendations, particularly those published by the National Comprehensive
Cancer Network (NCCN). We review the importance of a thorough history and physical examination, the impact of the American Joint Committee on Cancer (AJCC)
eighth edition changes and the importance of immunohistochemistry, the timing and
type of imaging, the role of panendoscopy and tonsillectomy (palatine and lingual),
and the role of surgery, radiation, and chemotherapy in the primary management of
these tumors.
KEYWORDS
cancer, education, guidelines, head and neck surgery, unknown primary

1 | INTRODUCTION
The following article adds to the series being published periodically in Head & Neck through an initiative by the American
Head and Neck Society’s (AHNS) Education Committee.
Here, we review clinical practice guidelines for head and neck
oncology, in this issue, focusing on the management of head
and neck cancers of unknown primary (CUP). The primary purpose of this series is to raise awareness of the current guidelines
in head and neck oncology by reviewing the recommendations
and the evidence supporting such recommendations, particularly those published by the National Comprehensive Cancer
Network (NCCN). The ultimate goal of this series is to improve
adherence to guidelines and improve patient outcomes.
Head and neck CUP origin comprises approximately 2%5% of all head and neck cancers, although the true incidence
614
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is probably lower with advances in surgical visualization and
radiological imaging to identify the primary site.1–3 There
has been a recent rise in CUP likely related to the increase in
human papillomavirus (HPV)-associated oropharyngeal cancers.4 All CUP are considered in the occult primary management pathway in the NCCN guidelines, as many of these
cancers convert from being CUP to having a known and discoverable primary site. Identifying the primary site is of the
utmost importance to help select the best treatment while
decreasing treatment-related morbidity and mortality.
The NCCN guidelines are developed by a group of
experts in the field based on their views of currently accepted
approaches to treatment through a series of statements of evidence and consensus. These guidelines are particularly useful
for cancers, such as CUP, in which there is no level 1 evidence. Nonetheless, the guidelines also recommend making
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treatment decisions based on the individual clinical circumstances and independent medical judgment allowing for personalization of care.
In this article, we discuss the diagnostic and treatment
approaches for patients with an occult primary, which is a
cervical node with CUP source, while reviewing the rationale
and evidence for these decisions.

1.1 | First steps — Thorough history and
physical examination
It is common for patients to present with a chief complaint of
a neck mass, and, in those over the age of 40 years, this often
leads to the diagnosis of a metastatic cancer. A thorough history and physical examination in this population, as recommended by the NCCN guidelines, will often identify a
primary tumor site in >90% of cases.3,5 The medical history
should include assessment of risk factors (tobacco or alcohol
use), previous malignancy (as those with a prior head and
neck cancer in the antecedent 5-year period may have a
regional recurrence), and any history of skin lesions/cancers.
A thorough physical examination should include fiber-optic
nasolaryngoscopy with visualization of the nasopharynx,
oropharynx, larynx, and hypopharynx. Palpation of the tonsils and tongue base adds additional information to fiberoptic examination and should always be performed in this
population. During fiber-optic examination, a variety of
maneuvers can assist in visualizing folded mucosal layers.6,7
Asking the patient to pull out their tongue can allow for better visualization of the tongue base and vallecula, whereas
asking the patient to puff out their cheeks allows better visualization of the pyriform sinuses. Neither of these maneuvers
is as good as visualization during direct endoscopy in the
operating room but they are certainly worthwhile maneuvers
that can improve yield of the in-office physical examination.

1.2 | Second step — Biopsy; impact of
American Joint Committee on Cancer eighth
edition update
Fine-needle aspiration (FNA) biopsy is a critical step in the
assessment of occult primary tumors of the neck after history
and physical examination. Core biopsy or open biopsy
should be avoided as these can interfere or change subsequent management and increases the risk of tumor seeding
along the biopsy tract. To improve the yield of the FNA,
ultrasound guidance can be utilized particularly for partially
cystic lymph nodes in which accessing the solid component
is of critical importance. Having access to an onsite pathology technician with cytopathologist at the time of the biopsy
can help confirm adequacy of the sample but this is not
always readily available at most institutions.8 Routine

|

615

assessment for p16 and Epstein-Barr virus can and should be
performed on FNA specimens.
Open biopsy before definitive neck dissection should be
avoided because of the risk of tumor spillage, challenging
revision surgery secondary to disruption of fascial planes,
and, above all, increased risk of local recurrence and distant
metastases.9 If an open biopsy is required, the patient should
be prepared for definitive management at the time of that
procedure, including a formal neck dissection. At the time of
the open biopsy, the incision should be planned in a position
that would make extension of the incision for a formal neck
dissection possible and frozen section biopsy can be performed, which if positive for squamous cell carcinoma
should lead to a formal neck dissection to better prognosticate the neck.10
Unknown primary cancers were not previously staged in
the American Joint Committee on Cancer (AJCC) seventh edition. However, it is included in the newest edition.11 The new
staging of CUP requires p16 immunohistochemical stains as a
surrogate for HPV-associated oropharyngeal cancers, and
Epstein-Barr virus-encoded RNA (EBER), which is associated
with nasopharyngeal cancer. Therefore, the FNA or open
biopsy/neck dissection specimen should be checked for p16
and EBER. Calcitonin can also be checked if medullary thyroid cancer is suspected. Thyroid-transcription factor can also
be tested to distinguish between lung squamous cell carcinoma
for which it is positive versus head and neck squamous cell
carcinoma for which it is usually negative. These advanced
immunohistochemical tests can help guide future endoscopy,
increasing the likelihood of finding the primary tumor site.
The recent changes in the AJCC have not yet impacted
the NCCN guidelines as it relates to the management of
unknown primary and oropharyngeal cancer p16 status. It is
quite likely that future editions of the NCCN guidelines will
reflect differences in the prognosis of these 2 different groups
of cancers (p16-positive vs negative), particularly as further
deescalation trials are completed. The remainder of this
review will be based on the NCCN recommendations based
on the seventh edition of the AJCC nodal classification. For
completeness, however, we do include a brief update on the
staging changes as it demonstrates the importance of p16 and
EBER testing.
Unknown primary cancers, which are p16-positive, are
staged as T0 and the N classification is based on the oropharyngeal clinical and pathologic groupings (Tables 1 and 2).
For patients with p16-positive CUP with information limited
to clinical staging, the N classification dictates the overall
stage (cN1 classification I; cN2 classification II; and cN3
classification III). Similarly, for those with pathologic staging, the N classification dictates the overall stage (cN1 classification I and cN2 classification II). If the EBER is positive,
the patients are staged as T0 and the N classification is based
on the nasopharyngeal nodal groupings. If the node is EBER
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p16-positive unknown primary and oropharynx clinical

nodal staging
N classification

N criteria

cN1

One or more ipsilateral lymph nodes,
none larger than 6 cm

cN2

Contralateral or bilateral lymph nodes,
none larger than 6 cm

cN3

Lymph node(s) larger than 6 cm

Abbreviation: cN, clinical N classification.
Republished with permission from the American Joint Committee on Cancer
(AJCC), Chicago, IL. The original source for this material is the AJCC Cancer
Staging Manual, Eighth Edition (2017) published by Springer Science and
Business Media LLC (springer.com). Amin MB, Edge SB, Greene FL, et al,
eds. AJCC Cancer Staging Manual. 8th ed. New York, NY, Springer, 2017,
with permission).

and p16-negative, the patients are staged as T0 and the nodal
classification is designated in the cervical nodes chapter,
which requires assignment of extranodal extension (ENE;
Table 3). Updated staging will be implemented in January
2018.

1.3 | Type and timing of imaging
If the FNA demonstrates a carcinoma and no primary site
has been found on physical examination, imaging studies
should be pursued before operative endoscopy with biopsy.
Conventional imaging, including CT and/or MRI, should be
pursued first. However, positron emission tomography with
CT fusion (PET-CT) is recommended in all patients if conventional imaging does not identify the primary site, as it can
often detect occult tumors >1 cm in size.
A number of excellent reviews on the topic of PET-CT
in the management of CUP have demonstrated its utility.
Yoo et al12 performed a thorough systematic review of the
literature in 2012 to make recommendations on this topic in
the context of a universal healthcare system. The high cost of
a PET-CT necessitated strong evidence to recommend this
imaging modality in this healthcare context.12 This excellent
T A BL E 2 The p16-positive unknown primary and oropharynx
pathologic nodal staging
N classification

N criteria

pN1

Metastasis in 4 or fewer nodes

pN2

Metastasis in >4 lymph nodes

Abbreviation: pN, pathological N classification.
Republished with permission from the American Joint Committee on Cancer
(AJCC), Chicago, IL. The original source for this material is the AJCC Cancer
Staging Manual, Eighth Edition (2017) published by Springer Science and
Business Media LLC (springer.com). Amin MB, Edge SB, Greene FL, et al,
eds. AJCC Cancer Staging Manual. 8th ed. New York, NY, Springer, 2017,
with permission).
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review highlights 3 landmark studies. The first, published in
2007, summarizes 2 systematic reviews, each with 8 primary
studies, and an additional 2 primary studies, demonstrating
that PET was able to detect the primary site in patients with
CUP, in 30% of those missed by conventional imaging.13 A
subsequent single institution study comparing PET-CT to
contrast-enhanced CT alone found a much higher rate of
detecting the primary tumor site with PET-CT.14 Last, a
Canadian prospective clinical trial demonstrated that patients
with cervical metastases from CUP benefited from PET-CT
before endoscopy and biopsy with higher detection rates secondary to more directed biopsies.15 Furthermore, this treatment approach has been demonstrated to be cost-effective,
particularly for N1 and N2 disease.16
Overall, PET-CT has a sensitivity of 43%-88%, specificity of 33%-88%, and a detection rate of 15%-50% in the management of CUP (Table 4).17–22 A recent systematic review
of 7 studies (246 patients) demonstrates an overall sensitivity
of 44% and specificity of 97%.23
Completing this imaging modality before diagnostic
endoscopy (nasopharyngoscopy, direct laryngoscopy, esophagoscopy, and bronchoscopy) is of the utmost importance, as
highlighted by the NCCN guidelines. Manipulation of the
tissues in the upper aerodigestive tract specifically with
biopsy may lead to false-positive results on the PET-CT
from inflammation at the biopsy site, thereby decreasing the
diagnostic yield of the PET-CT. Furthermore, having these
results before operative endoscopy allows the surgeon to
focus on particular high-risk sites, as identified on the PETCT for biopsy.19 The introduction of PET-CT has improved
detection rates with 1 study demonstrating preintroduction
and postintroduction of PET-CT detection rates of 40.5%
and 59.6%, respectively (P 5 .02).19
An additional benefit of PET-CT imaging is the detection
of previously undiagnosed distant metastases in 11% of cases
and regional disease in 15% of cases.17
In addition to all of the aforementioned head and neck
imaging, the NCCN guidelines also recommend imaging the
chest, abdomen, and pelvis with CT (or PET-CT) in those
patients with level IV and low level V metastatic nodes on
presentation, as these sites can harbor the primary site.10

1.4 | Panendoscopy and directed biopsy
(include levels of neck as algorithm)
The NCCN guidelines make recommendations regarding
endoscopy and directed biopsies based on the levels of the
neck involved. For those patients with a level IV or low level
V metastatic node, in addition to the aforementioned imaging
recommendations, the guidelines recommend examination
under anesthesia, including direct laryngoscopy, esophagoscopy, and bronchoscopy.10 On the other hand, for patients
with levels I, II, III, or high level V nodes, the guidelines
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The p16-negative and Epstein-Barr virus-encoded RNA-negative unknown primary clinical and pathological nodal staging

N classification

N criteria

N1

Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE-negative

N2a

Metastasis in a single ipsilateral lymph node larger than 3 cm but not larger than 6 cm in greatest
dimension and ENE-negative

N2b

Metastasis in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE-negative

N2c

Metastasis in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE-negative

N3a

Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE-negative

N3b

Metastasis in any node(s) and clinically overt ENE-positive

Abbreviation: ENE: extranodal extension.
Republished with permission from the American Joint Committee on Cancer (AJCC), Chicago, IL. The original source for this material is the AJCC Cancer Staging
Manual, Eighth Edition (2017) published by Springer Science and Business Media LLC (springer.com). Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer
Staging Manual. 8th ed. New York, NY, Springer, 2017, with permission).

recommend examination of the larynx and nasopharynx
through nasolaryngoscopy, inspection and palpation of the
oral cavity and oropharynx, examination under anesthesia
with biopsies of areas of clinical concern, and finally a tonsillectomy with or without lingual tonsillectomy if a primary is
not identified on the previous steps.10 The different
approaches based on nodal level are directly related to the
primary site association with nodal levels. Most (74%) CUP
are from the oropharyngeal subsite, specifically the tonsils
and base of tongue, and, therefore, increased attention should
be paid to these subsites on endoscopy.19 Palpation of these
subsites, a maneuver not well tolerated by all patients in the
clinic, provides important additional tactile information and
increases the likelihood of identifying a primary in the high
yield subsites.
The NCCN guidelines do not make specific recommendations on sidedness of the tonsillectomy and in which cases a
lingual tonsillectomy is indicated. The literature clearly identifies that at the very least a tonsillectomy is superior to deep
tonsil biopsies, increasing the likelihood of finding a primary
in the tonsils by 30%, likely due to the crypt architecture of the
tonsils making some of these cancers not visible on physical
examination.24–26 A contralateral tonsillectomy identifies the
primary tumor in 15%-25% of cases (Table 5)27–29 and,
T A BL E 4

therefore, if a patient has tonsillar tissue present, bilateral tonsillectomies increases the detection rate.27–29 This is reasonable
given the minimal additional morbidity of bilateral tonsillectomy to unilateral tonsillectomy. Furthermore, performing a
unilateral tonsillectomy may produce confusion and raise anxiety on follow-up examination in this patient population.
Blind biopsies of the nasopharynx, pyriform sinus, and
hypopharynx, in the absence of suspicious clinical or radiographic findings, is no longer indicated in the NCCN guidelines because of the low incidence of cancers at these
subsites.
However, management of the base of tongue is more
controversial. The NCCN guidelines offer the option of performing a lingual tonsillectomy while not specifying whether
this can be performed unilaterally or bilaterally. A formal lingual tonsillectomy, defined as a resection of the base of
tongue tissue in the muscular layer as the deep plane of dissection, from midline of the tongue to the lateral pharyngeal
wall and from the circumvallate papillae to the vallecula, has
increased in popularity due to advances in operative techniques that include improved visualization and instrumentation
with transoral laser microsurgery and transoral robotic surgery. One study demonstrated a 90% tumor identification
(mean diameter 0.9 cm) with transoral robotic base of tongue

Scoping review of positron emission tomography-CT detection rates in cancers of unknown primary

Study

Sample size

Sensitivity

Specificity

Detection rate

302

88%

75%

25%

Yaylali et al18

50

88%

33%

50%

Waltonen et al19

52

43%

72%

15%

Lee et al

56

69%

88%

50%

Karapolat and Kumanlioglu21

20

87%

83%

35%

Majchrzak et al22

41

69%

86%

17%

Rusthoven et al

17

20
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Rate of contralateral or bilateral tonsillar disease in cancers of unknown primary

Study

Sample size

Koch et al27
28

Kothari et al
Fu et al29

ET AL.

Study type

Rate of contralateral or bilateral tonsil disease

16

Single institution

25% (12.5% bilateral and 12.5% contralateral)

22

Single institution

23%

139

Systematic review

15%

resection when PET-CT, formal endoscopy, and bilateral
tonsillectomy were all negative for malignancy in patients
with CUP.30 Similarly, Graboyes et al31 demonstrated an
89% detection rate using this approach in the p16-positive
population. A systematic review on the additional benefit of
formal lingual tonsillectomy in the assessment of patients
with CUP, which included a total of 8 studies and 139
patients, demonstrated a detection rate of 56% when lingual
tonsillectomy was performed.29 This is likely because PETCT misses subcentimeric tumors and the average tumor size
identified in this review was just over 1 cm.29 It is, therefore,
not surprising that the most recent NCCN guidelines no longer recommend random base of tongue biopsies as the likelihood of identifying these subcentimeric tumors with this
approach is low. Therefore, a unilateral lingual tonsillectomy
is indicated at the time of tonsillectomy when no primary
can be identified. Some have advocated for a bilateral lingual
tonsillectomy, as 6% of the contralateral lingual tonsillectomy specimens were positive for carcinoma29; however, this
does carry an increased risk in addition to the additional rare
complication of oropharyngeal stenosis with a nearly circumferential mucosal raw surface.32
In the next section of the article, we review the accepted
NCCN treatment algorithm for CUP when the primary site is
not identified focusing on the unique role of surgery, radiation, and systematic therapy. The NCCN guidelines provide
clear recommendations regarding each therapy and are far
more prescriptive than for most other head and neck cancer
subsites.

1.5 | The role of surgery (neck dissection) —
N1 disease
Primary surgery (neck dissection) is preferred over radiotherapy for patients with N1 disease (a single lymph node <3
cm in size) based on the seventh AJCC classification.10
There are 2 main reasons for this clear preference in primary
treatment: (1) neck dissection provides important prognostic
information that can help determine important adjuvant treatment; and (2) because surgery provides the best chance of
regional disease control without missing a significant number
of primary tumors.
Extracapsular extension (ECE), the most important pathologic predictor for the use of systematic therapy, is not

accurately diagnosed on contrast-enhanced neck CT by
expert neuroradiologists, making surgery the primary and
best method of diagnosing ECE.33 Neck dissection often
identifies more extensive disease upstaging approximately
one third of patients with more than 1 lymph node or ECE in
the clinically N1 presentation.5
Comparing surgery and radiotherapy alone, surgery is
cheaper, faster, and has less morbidity particularly as it
relates to swallowing dysfunction. There is some evidence
that surgery alone (neck dissection) in patients with N1 disease followed by observation is reasonable and this is listed
as a treatment option by the NCCN guidelines when there is
no ECE.10 However, historic evidence demonstrates that
patients receiving surgery alone have a higher rate of tumor
discovery in the posttreatment period than if they had
received radiotherapy (with or without neck dissection)2 and,
therefore, most patients with N1 unknown primary tumors
without ECE post-neck dissection are treated with adjuvant
radiotherapy, which is also listed as a treatment option in this
group by the NCCN guidelines.34

1.6 | The role of radiation
Primary radiotherapy (with chemotherapy) is the main treatment used for unknown primary cancers of the head and
neck because it addresses mucosal surfaces at the same time
as the regional neck disease and has been shown to decrease
the rate of primary tumor discovery in the posttreatment
period. Therefore, the NCCN guidelines recommends
postoperative radiotherapy for patients with N2/N3 disease
(without ECE) and also suggests “considering” systemic
therapy.10 It should be noted, however, that there have been
no trials comparing neck dissection followed by radiotherapy
versus concurrent chemoradiotherapy in patients with greater
than or equal to N2 CUP.
When radiotherapy is used, treatment volumes include
bilateral mucosal surfaces and both sides of the neck. This is
associated with improved disease-free survival, lower primary tumor discovery, and contralateral neck disease recurrence when compared with patients treated with unilateral
radiotherapy to the neck and mucosal surfaces.35,36
The NCCN guidelines recommend 70 Gy dosing for the
primary nodal disease levels, 50 Gy to the lower-risk neck
sites (contralateral neck and uninvolved levels, including the
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retropharyngeal nodes), and 60-66 Gy for at-risk mucosal
sites.10 Historically, patients would receive radiation to the
nasopharynx, oropharynx, larynx, and hypopharynx in addition to the bilateral sides of the neck. This is associated with
significant morbidity with an average of 60-66 Gy to all
sites, despite advanced intensity-modulated radiotherapy
technology. In the era of oropharyngeal-associated HPV disease, some have advocated only radiating the oropharynx
and bilateral sides of the neck with inclusion of the retropharyngeal nodes, particularly for those patients with HPVpositive tumors.37 Although this approach is discussed by
the NCCN guidelines, which suggests that treatment volume
should be determined by the nodal levels involved, tumor
size and HPV/Epstein-Barr virus status, there is very little literature on this approach compared to the conventional treatment approach. The NCCN guidelines clarify that if HPV
status is to be used to change treatment volumes, this should
only be performed in the context of a clinical trial. One
study, with a small sample size (n 5 17), demonstrated that
larynx and hypopharynx-sparing radiotherapy in the management of CUP is safe with comparable survival and recurrence
outcomes while providing a lower toxicity profile.38 As the
lower treatment volume approach is increasingly used by
some centers, retrospective data will be available in the coming years to compare these 2 approaches, although due to the
relative rarity of CUP this will take many years. A collaborative multi-institutional trial should be considered to answer
this question, as suggested by the NCCN.

1.7 | Chemotherapy (N2, N3, and any
extracapsular extension)
Chemotherapy is indicated for patients with ECE, as demonstrated by the landmark Radiation Therapy Oncology Group
and European Organization for Research and Treatment of
Cancer 2004 studies, which were studied in combination by
Cooper et al39 Bernier et al40,41 in 2004 and 2005. These
studies highlight the importance of the prognostic information afforded by a neck dissection for patients who would
otherwise receive radiotherapy alone without systemic therapy (N1 disease).39–41 The NCCN recommends chemoradiotherapy when ECE is present, although it should be noted
that there are no randomized trials demonstrating this treatment approaches’ utility or superiority over radiotherapy
alone in the CUP population. Furthermore, systematic therapy can be considered in addition to radiotherapy in the postoperative setting for patients with N2/N3 disease without
ECE. Functional outcome data are not available for this particular subgroup of patients; however, outcomes are directly
related to tissue toxicity depending on the field and dose of
radiation, the number of modalities used as primary treatment
and cumulative, and the type of radiotherapy used. There are
similar survival outcomes among patients with T1 base of

619

tongue cancers and patients with CUP demonstrating that, if
the primary is found, a lower dose with narrower field may
impact functional outcomes, although this has not been specifically studied.42

1.8 | Follow-up and surveillance
Follow-up posttreatment is the same for CUP and other head
and neck cancers; every 1-3 months in the first year, every 2
to 6 months in the second year, and every 4-8 months in the
third year. A posttreatment scan within 6 months of treatment
can also be used to assess treatment response regardless of
the treatment modality used.10 In situations in which there is
an inadequate response in the neck from a nonsurgical
approach with persistence of a neck mass, a PET-CT scan
can be used with an excellent negative predictive value.12
This approach, in patients treated nonsurgically with
advanced neck disease, has been demonstrated to be more
cost-effective with similar survival compared to a planned
neck dissection in the posttreatment period.43–45

2 | CONCLUSION
The incidence of CUP is increasing but with advances in
immunohistochemical staining, imaging, and intraoperative
visualization of high-risk subsites has increased the likelihood of identifying the primary site. The PET-CT scans are
indicated for CUP before surgical endoscopy and biopsies.
In those patients in whom the primary site is not identified,
bilateral tonsillectomy with lingual tonsillectomy is indicated. Neck dissection is recommended for N1 disease. For
N2 disease without ECE, the NCCN recommends radiotherapy with the option of considering systemic therapy. For
patients with ECE, systemic therapy is indicated.
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